Key Points
- Chairman Morgan Lee Lekstrom bought 50,000 Biosig Technologies shares on June 12 at an average price of $0.99, spending $49,500. The purchase lifted his holdings to 359,500 shares, a 16.16% increase in ownership.
- Lekstrom has been actively buying the stock in recent weeks, including purchases of 34,000 shares on May 28 and 147,000 shares on May 21. He also sold 12,759 shares in April, showing a mix of insider activity.
- Biosig Technologies recently reported a quarterly loss of ($0.27) per share, and analysts currently have a Hold consensus with an average price target of $8.00. The stock was trading around $1.01, far below its 52-week high of $14.11.
Biosig Technologies, Inc. (NASDAQ:STEX - Get Free Report) Chairman Morgan Lee Lekstrom purchased 50,000 shares of the stock in a transaction that occurred on Friday, June 12th. The shares were acquired at an average cost of $0.99 per share, with a total value of $49,500.00. Following the completion of the transaction, the chairman owned 359,500 shares in the company, valued at $355,905. This trade represents a 16.16% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.
Morgan Lee Lekstrom also recently made the following trade(s):
- On Thursday, May 28th, Morgan Lee Lekstrom purchased 34,000 shares of Biosig Technologies stock. The shares were acquired at an average cost of $1.47 per share, with a total value of $49,980.00.
- On Thursday, May 21st, Morgan Lee Lekstrom purchased 147,000 shares of Biosig Technologies stock. The shares were acquired at an average cost of $1.04 per share, with a total value of $152,880.00.
- On Tuesday, April 14th, Morgan Lee Lekstrom sold 12,759 shares of Biosig Technologies stock. The shares were sold at an average price of $1.07, for a total transaction of $13,652.13.
Biosig Technologies Stock Performance
Shares of NASDAQ STEX opened at $1.01 on Tuesday. Biosig Technologies, Inc. has a 1 year low of $0.70 and a 1 year high of $14.11. The stock has a market cap of $183.62 million, a PE ratio of -0.10 and a beta of 1.84. The company's 50-day simple moving average is $1.07.
Biosig Technologies (NASDAQ:STEX - Get Free Report) last issued its earnings results on Thursday, May 14th. The company reported ($0.27) earnings per share (EPS) for the quarter.
Analysts Set New Price Targets
Several research analysts have issued reports on the stock. Weiss Ratings raised shares of Biosig Technologies from a "sell (e+)" rating to a "sell (d-)" rating in a report on Friday, May 1st. Wall Street Zen cut shares of Biosig Technologies from a "hold" rating to a "strong sell" rating in a report on Sunday, April 5th. Finally, Needham & Company LLC decreased their target price on shares of Biosig Technologies from $9.00 to $8.00 and set a "buy" rating for the company in a report on Thursday, May 21st. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $8.00.
Get Our Latest Analysis on Biosig Technologies
Biosig Technologies Company Profile
(
Get Free Report)
Biosig Technologies (NASDAQ:STEX) is a medical technology company focused on developing advanced signal acquisition and processing solutions for cardiac electrophysiology. The company’s work centers on improving the clarity and interpretability of intracardiac signals captured during electrophysiology procedures, with the goal of helping clinicians identify arrhythmogenic substrates and make more informed procedural decisions.
Its primary offering is a signal-processing platform that combines proprietary hardware and software to amplify, filter and display intracardiac electrical activity with reduced noise and distortion.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
